Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes
Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · 421-435
DOI: 10.1016/j.ecl.2026.04.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Rachael Innes und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Merck KGaA, Sanofi.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Phase 2 clinical trials using daily injectable glucagon-like peptide-1 receptor agonists as adjunct therapy in type 1 diabetes showed promising signals for efficacy on glycemic control and weight. These effects were confirmed in larger phase 3 trials but accompanied by safety issues including hypoglycemia and ketosis. Of note, these trials were conducted before the availability of widespread continuous glucose monitoring (CGM) and used simple one size fits all rules for insulin dose titration. Attention has moved on to weekly injectable agents at present, with more individualized insulin titration and guided by CGM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
- School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, Robertson Centre for Biostatistics/ Glasgow Clinical Trials Unit, University of Glasgow, Glasgow, UK.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Endocrinology and Nephrology, Nordsjællands Hospital - Hillerød, Hillerød, Denmark. E…
Förderung
- Merck KGaA
- Sanofi
Zitieren
APA
Innes, R., Petrie, J. R., & Dejgaard, T. F. (2026). Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 55(3), 421-435. https://doi.org/10.1016/j.ecl.2026.04.002
Vancouver
Innes R, Petrie JR, Dejgaard TF. Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. 2026;55(3):421-435. doi:10.1016/j.ecl.2026.04.002
BibTeX
@article{Innes2026,
author = {Innes, Rachael and Petrie, John R and Dejgaard, Thomas Fremming},
title = {Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes},
journal = {Endocrinology and Metabolism Clinics of North America},
year = {2026},
volume = {55},
number = {3},
pages = {421--435},
doi = {10.1016/j.ecl.2026.04.002}
}
EUVIMED